Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Depreciation & Amortization (CF) of $1000.0 for Q1 2026, little changed year-over-year from $1000.0 in Q1 2025, and little changed quarter-over-quarter from $1000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $1000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $4000.0 (down 93.94% YoY), and the FY2025 annual result was $4000.0, down 95.92% from the prior year.
- Depreciation & Amortization (CF) held at $1000.0 in Q1 2026 per AMRN's latest filing, from $1000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $144000.0 in Q1 2022 and troughed at $1000.0 in Q1 2025.
- A 5-year average of $47882.4 and a median of $32000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) gained 3.23% in 2024, then tumbled 96.97% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $125000.0 in 2022, then slumped by 73.6% to $33000.0 in 2023, then slumped by 75.76% to $8000.0 in 2024, then slumped by 87.5% to $1000.0 in 2025, then changed by 0.0% to $1000.0 in 2026.
- Business Quant data shows AMRN's Depreciation & Amortization (CF) at $1000.0 in Q1 2026, $1000.0 in Q4 2025, and $1000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 509.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 188.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 594.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Mar 31, 2024 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |